Shanghai INT Medical Instruments Co., Ltd. has announced the placing of new H shares under a general mandate. The company’s shares involved in this transaction have not been and will not be registered under the U.S. Securities Act of 1933, meaning they may not be offered or sold in the United States except pursuant to an exemption from registration. The placing is subject to the approval of the Hong Kong Stock Exchange, and the company will also complete necessary filings with the China Securities Regulatory Commission. The proceeds from the placement are expected to support the company’s operations as a leading Chinese vascular interventional device manufacturer, which covers the full industry chain from design and development to sterilization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Int Medical Instruments Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260114-11991190), on January 14, 2026, and is solely responsible for the information contained therein.